Table 2.
Association between dietary magnesium or calcium intake and the prevalence of chronic chemotherapy-induced neuropathy in colorectal cancer patients receiving adjuvant chemotherapy.
| n/Events | Prevalence Ratio (95% CI) Total Score CIPN16 1 | n/Events | Sensory Symptoms 1 | n/Events | Motor Symptoms 1 | |
|---|---|---|---|---|---|---|
| Magnesium intake | ||||||
| Crude model | ||||||
| At diagnosis | 194/158 | 0.81 (0.51, 1.29) | 194/157 | 0.98 (0.64, 1.52) | 194/147 | 0.95 (0.54, 1.67) |
| During chemotherapy | 192/156 | 0.57 (0.35, 0.92) | 192/156 | 0.70 (0.44, 1.12) | 192/145 | 0.59 (0.33, 1.05) |
| After chemotherapy | 181/147 | 0.67 (0.43, 1.05) | 181/146 | 0.86 (0.57, 1.31) | 181/136 | 0.61 (0.36, 1.03) |
| Full model | ||||||
| At diagnosis | 194/158 | 0.69 (0.42, 1.13) | 194/157 | 0.84 (0.51, 1.39) | 194/147 | 0.81 (0.43, 1.52) |
| During chemotherapy | 192/156 | 0.53 (0.32, 0.90) | 192/156 | 0.67 (0.40, 1.10) | 192/145 | 0.57 (0.30, 1.09) |
| After chemotherapy | 181/147 | 0.61 (0.37, 1.03) | 181/146 | 0.84 (0.51, 1.37) | 181/136 | 0.51 (0.28, 0.93) |
| Calcium intake | ||||||
| Crude model | ||||||
| At diagnosis | 194/158 | 1.15 (0.93, 1.41) | 194/157 | 1.20 (0.98, 1.46) | 194/147 | 1.12 (0.89, 1.41) |
| During chemotherapy | 192/156 | 0.97 (0.83, 1.13) | 192/156 | 1.02 (0.87, 1.19) | 192/145 | 0.89 (0.73, 1.09) |
| After Chemotherapy | 181/147 | 1.03 (0.86, 1.23) | 181/146 | 1.08 (0.90, 1.30) | 181/136 | 0.96 (0.78, 1.17) |
| Full model | ||||||
| At diagnosis | 194/158 | 1.21 (0.95, 1.56) | 194/157 | 1.24 (0.97, 1.58) | 194/147 | 1.15 (0.88, 1.50) |
| During chemotherapy | 192/156 | 1.03 (0.86, 1.23) | 192/156 | 1.06 (0.89, 1.28) | 192/145 | 0.92 (0.73, 1.16) |
| After Chemotherapy | 181/147 | 1.08 (0.89, 1.32) | 181/146 | 1.10 (0.89, 1.35) | 181/136 | 0.99 (0.79, 1.24) |
Analyses were performed using a Cox proportional hazard regression model, with a fixed time variable. Crude models: energy-adjusted intake of magnesium or calcium. Full model for magnesium was adjusted for, energy-adjusted dietary calcium and vitamin D intake as well as age and gender. Full model for calcium was adjusted for, energy-adjusted dietary magnesium and vitamin D intake as well as age and gender. 1 CIPN was defined as a score >3.6 for the total CIPN16 score, >3.2 for the sensory sub-score and >3.8 for the motor sub-score.